Wnt signaling plays an important role in stem cell self-renewal and proliferation. Aberrant activation of Wnt signaling and its downstream targets are intimately linked with several types of cancer with colon cancer being the best-studied example. However, recent results also suggest an important role of Wnt signaling in normal as well as leukemic hematopoietic stem cells. Aberrant activation of Wnt signaling and downstream effectors has been demonstrated in acute myeloid leukemia. Here, mutant receptor tyrosine kinases, such as Flt3 and chimeric transcription factors such as promyelocytic leukemia-retinoic acid receptor-a and acute myeloid leukemia1-ETO, induce downstream Wnt signaling events. These findings suggest that the Wnt signaling pathway is an important target in several leukemogenic pathways and may provide a novel opportunity for targeting leukemic stem cells.
Introduction
Acute myeloid leukemia (AML) is a clonal disease resulting from a malignant transformation of a hematopoietic stem or progenitor cell. It is characterized by an abnormal accumulation of hematopoietic progenitor cells leading to progressive insufficiency of normal hematopoiesis. Over the last decades, considerable progress has been achieved in the elucidation of the molecular pathogenesis of this disease. The major types of genetic events in the development of AML comprise alterations in myeloid transcription factors and activating mutations of signal transduction intermediates leading to inappropriate gene expression and aberrant signal transduction, respectively. Both mechanisms are highly interdependent, resulting in reduced apoptosis, increased stem cell self-renewal and blocked differentiation of AML cells. 1 It is supposed that AML arises from the malignant transformation of a normal hematopoietic stem or progenitor cell into a cancer stem cell. Normal embryonic and hematopoietic stem cells (HSCs) possess the unique properties of self-renewal and the ability to develop into multiple lineages with generation of more differentiated progenies.
2 Therefore, HSCs are considered to be bona fide candidates for the accumulation of multistep, genetic mutations transforming them into a cancer stem cell. [3] [4] [5] Another hypothesis is that hematopoietic progenitor cells may regain stem cell properties owing to oncogenic mutations finally leading to the initiation of leukemia. [6] [7] [8] [9] In various types of leukemia, cancer stem cells have been detected, and several features of these leukemia stem cells (LSCs) have been described. [10] [11] [12] The LSC concept is well established in myeloid leukemia. 3, 13, 14 In many instances, AML initially responds well to chemotherapy but relapse of the disease occurs in the majority of patients. Relapse after eradication of bulk disease by chemotherapy is a common event in many types of solid malignant tumors and a plausible explanation might be a failure to eliminate cancer stem cells.
2 Accordingly, in leukemia patients, LSCs have been shown not to be targeted by current chemotherapy regimens and thus might account for drug resistance and relapse. 4, 5 In this regard, the frequency of relapse in AML might be attributed to the persistence of LSCs. Similar to normal HSCs, LSCs harbor the potentials of self-renewal and continuous proliferation that may account for regrowth of the disease.
Within the last years, the critical role of Wnt signaling in stem cells has been elucidated. 15, 16 The Wnt pathway regulates cell fate and differentiation decisions during embryogenesis and in adult stem cells. The mechanisms of self-renewal and proliferation are tightly regulated in normal stem and progenitor cells. In various tissues, activation of Wnt signaling has been associated with cancer [17] [18] [19] [20] [21] [22] promoting the hypothesis that self-renewal and proliferation are subverted in cancer cells allowing malignant growth. Wnt signaling has also been implicated in self-renewal and proliferation of hematopoietic stem and progenitor cells, 23, 24 suggesting an involvement in leukemogenesis. Recently, many studies confirmed a crucial role of Wnt signaling in leukemia, shifting this pathway progressively into the spotlight of AML research.
The canonical Wnt pathway
The Wnt pathway is evolutionary highly conserved and plays a critical role in the development of many organ systems. The human genome harbors almost 20 Wnt genes, all of which encode lipid-modified secreted glycoproteins 25 regulating developmental processes. 26 Three different intracellular Wnt signaling pathways have been described including the canonical pathway, an only partially understood pathway involving calcium ions, and the planar-cell-polarity pathway. [27] [28] [29] [30] [31] The non-canonical signaling pathways induced by Wnt have recently been reviewed by Veeman et al. 32 Signaling of the canonical Wnt pathway is initiated by binding of Wnt ligands to their receptor complex, consisting of a receptor of the Frizzled family and a co-receptor of the low-density lipoprotein (LDL)-receptor-related-protein family LRP5 or LRP6. [33] [34] [35] [36] The key mediator of the canonical Wnt pathway is b-catenin (Figure 1 ). b-Catenin is a cytoplasmatic protein with a very short half-life owing to the activity of a multiprotein destruction complex that contains the tumor-suppressor gene products axin and adenomatous polyposis coli (APC) as well as the serine/ threonine kinases GSK3b (glycogen-synthase kinase 3b) and CK1 (casein kinase 1). [37] [38] [39] Despite some contradictory data partially favouring a positive signal transducing function of CK1 within the Wnt pathway, [40] [41] [42] this protein mainly appears to have an inhibiting role by promoting targeted b-catenin degradation. [43] [44] [45] CK1 activity is regulated by various mechanisms, including autophosphorylation, dephosphorylation and proteolytic cleavage. [46] [47] [48] [49] In the absence of Wnt, after binding axin and APC, newly synthesized b-catenin is sequentially phosphorylated on several serine and threonine residues by CK1 and GSK3b. Phosphorylation results in the recognition by b-TRCP (b-transducin-repeatcontaining protein), which leads to the ubiquitination and subsequently proteasomal degradation of b-catenin. 50 Members of the TCF (T-cell factor)/LEF (lymphocyte-enhancer-binding factor) family remain inactivated in the nucleus owing to groucho-related transcriptional repressors (grg). As a consequence of Wnt binding to Frizzled and LRP5/6 the multiprotein destruction complex is destabilized by an incompletely understood mechanism involving the direct interaction of axin with LRP5/6 and/or the actions of Dishevelled (DVL), an axin-binding molecule. It has been demonstrated that after Wnt signaling, DVL is recruited to the cell membrane, allowing dissociation of GSK3b from axin. This process is enhanced by Galpha protein signaling. 51 When binding of GSK3b to b-catenin is disrupted, phosphorylation of b-catenin does not occur. [52] [53] [54] Thus, unphosphorylated b-catenin accumulates and subsequently translocates to the nucleus, where it replaces the groucho-related repressors and acts as a transcriptional co-activator for TCF/LEF target genes. 55, 56 The transcriptional activity of b-catenin also depends on two additional nuclear proteins, pygopus homologue (PYGO) and Bcl9, a putative proto-oncogene. Bcl9 functions as an adaptor between PYGO and TCF-bound b-catenin, 57-60 a mechanism that is essential for transcriptional activation of TCF/LEF target genes.
The canonical Wnt pathway is regulated on different levels of the cascade. Various secreted molecules extracellularly interfere with Wnt ligand binding to its Frizzled-LRP5/6 receptor complexes. For example, the four mammalian homologues of Dickkopf (DKK), DKK1-4, are negative regulators of Wnt signaling by interacting with the Wnt co-receptor LRP5/6, thereby inhibiting signals that emanate from the Frizzled-LRP complex. Frizzled-related proteins (FRPs) are naturally occuring secreted forms of Frizzled, which contain the cysteine-rich domain of members of the Frizzled-family but do not dispose of a transmembrane region. Thus, they can bind Wnt proteins in solution and thereby abrogate the activity of Wnts. Furthermore, the transcriptional activity of the b-catenin-TCF complex is modulated within the nucleus. ICAT (inhibitor of b-catenin and TCF) and Chibby have been shown to inhibit b-cateninmediated transcriptional activation by competing with LEF1 for binding to b-catenin. 61, 62 Moreover, the canonical Wnt pathway is inhibited by DVLbinding partners like Nkd and Stbm. 63, 64 Another DVL-binding partner is the adaptor molecule Disabled-2 (Dab2), 65 which has been shown to participate in regulation of several signaling pathways. 66 , 67 Hocevar et al. 65 identified that the N-terminal domain of Dab2 interacts with Dishevelled-3 (DVL-3). Ectopic expression of Dab2 attenuates canonical Wnt/b-cateninmediated signaling in NIH-3T3 mouse fibroblasts. They also showed that Wnt stimulation leads to a time-dependent dissociation of endogenous Dab2-DVL-3 and DVL-3-axin interactions in NIH-3T3 cells, while Dab2 overexpression leads to inhibition of cytosolic and nuclear b-catenin accumulation as well as to maintenance of Dab2-DVL-3 association and subsequent loss of DVL-3-axin interactions. Dab2-deficient mouse embryo fibroblasts exhibit constitutive Wnt signaling as evidenced by increased levels of nuclear b-catenin/TCF/LEF-1-dependent gene induction. 65 Thus, Dab2 was identified as a negative regulator of canonical Wnt signaling by stabilizing the b-catenin degradation complex. Control of DVL-binding partners thus appears to be an important regulatory component of the Wnt signaling pathway.
Dysregulated Wnt signaling has been identified as a key factor in the initiation of various types of cancer. Several transcriptional targets of Wnt signaling are known oncogenes in the pathogenesis of epithelial cancers. 68 For example, two of the TCF/LEF target genes, c-myc and cyclin D1 are supposed to be involved in the oncogenic function of inappropriate Wnt signal activation. 69, 70 Wnt signals appear to provide antiapoptotic signals by inducing the antiapoptotic protein BCL-X L . 71 Moreover, the Wnt signaling pathway has recently been implicated in self-renewal and proliferation of hematopoietic stem and progenitor cells.
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Wnt signaling in HSCs
Similar to other stem cells, HSCs harbor the properties of selfrenewal, asymmetric cell division and the potential to differentiate into multiple lineages. In recent years, the Wnt signaling pathway has been implicated to contribute to self-renewal and proliferation of hematopoietic stem and progenitor cells. 23, 24, [72] [73] [74] [75] Austin et al. 23 demonstrated a role of Wnt signaling in the induction of proliferation of early murine hematopoietic cells. Transfection of stromal cells with mouse Wnt1, Wnt5a or Wnt10b resulted in proliferation of AA4 þ cKIT þ SCA1 þ mouse fetal liver cells, a cell population highly enriched in HSC activity. Moreover, treatment of mice with Wnt5A-conditioned medium resulted in increased human HSC re-population in a NOD-SCID xenotransplant model. 72 Plakoglobin (g-catenin), a target downstream of b-catenin within the Wnt pathway, accelerates cell cycle progression of HSCs. 76 Overexpression of plakoglobin leads to enhanced re-plating capacity of HSCs and selectively causes expansion of colonies of immature cells in vitro. 76 Inhibition of Wnt signaling by ectopic expression of axin results in decreased growth of HSCs in vitro and in vivo. Self-renewal of HSCs is enhanced through the canonical Wnt pathway and mediated by the lymphoid enhancer factor 1/T-cell transcription factor (LEF-1/TCF) complex. 73 b-Catenin as well as purified Wnt3A protein can promote self-renewal of murine HSCs in vitro and increase their capacity to reconstitute the hematopoietic system of lethally irradiated mice in vivo.
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Wnt3a activates b-catenin by stabilizing it in the cytosol and induces known Wnt targets, such as Myc, cyclin D1 and MSX1. 74 Apparently, HSCs are able to synthesize Wnt proteins binding to the Frizzled-LRP5/6-receptor complex, suggesting an autocrine or paracrine mechanism for the stimulation of selfrenewal through Wnt signaling in those cells. [78] [79] [80] Furthermore, recent findings indicate that Wnt proteins are not only produced by HSCs themselves but are also released from bone marrow stromal cells. 23, 77, 81, 82 Within the bone marrow, HSCs reside in small niches and are surrounded by other cells and matrix components constituting the microenvironment. The heterogenous cell population of the HSC microenvironment includes fibroblasts, adipocytes, endothelial cells and osteoblasts, all derived from a common mesenchymal precursor. 83 Several studies revealed a critical role of Wnt signaling for communication between HSCs and cells of the microenvironment, and particularly with osteoblasts. [78] [79] [80] 84, 85 These interactions also contribute to HSC self-renewal.
Other signaling pathways that increase self-renewal and proliferation of HSCs include sonic hedgehog 86 and Notch. 87 The Wnt signaling pathway interacts with the Notch pathway. 88 For example, Notch1 is upregulated in response to Wnt signaling in HSCs, raising the possibility that Wnt exerts its influence also by activating Notch1 target genes. 73, 89 The Wnt and Notch pathway have both been implicated in self-renewal of HSCs 75, 89, 90 and cooperation between Wnt and Notch in HSCs has recently been suggested by Duncan et al. 89 Recent studies have demonstrated that the Wnt/b-catenin pathway must be well controlled to assure normal hematopoiesis, because constitutive activation of Wnt signaling results in multilineage differentiation block and compromised HSC maintenance. 91, 92 Taken together, Wnt signaling mediates stimulation of self-renewal and enhanced proliferation of HSCs, as well as reduced differentiation. These are features, which might contribute to leukemogenesis.
Wnt signaling in AML
Dysregulated Wnt signaling has become a hallmark in various types of epithelial cancers. 54, 68 The role of the Wnt pathway for survival, proliferation and differentiation of HSCs has raised the hypothesis that aberrant Wnt signaling might also contribute to the pathogenesis of leukemia.
AML is frequently associated with mutations of the Flt3 receptor tyrosine kinase (RTK) as well as with chromosomal translocations, such as t(15;17) and t(8;21), resulting in the generation of chimeric genes encoding specific transcription factors. Both, chromosomal translocations and Flt3 mutations have recently been reported to be associated with aberrant Wnt signaling in AML (Figure 2 ). However, some AML patients neither harbor chromosomal translocations nor Flt3-mutations but still show aberrant Wnt signaling, suggesting mechanisms of aberrant Wnt signaling in AML independent from these mutations.
Activation of Wnt signaling by translocation products in AML
The AML-associated translocation products AML1-ETO, promyelocytic leukemia-retinoic acid receptor-a(PML-RARa), and promyelocytic zink finger protein (PLZF)-RARa encode aberrant transcription factors that induce self-renewal capacity and a differentiation block in susceptible hematopoietic cells. Using high-density oligonucleotide, microarray analyses shared target genes of the fusion proteins AML1-ETO, PML-RARa and PLZFRARa in inducibly transfected U937 cells have recently been identified, and several of the genes regulated by all three fusion proteins have been found to be associated with Wnt signaling. 93 One of the positive transcriptional regulators strongly induced on the mRNA and protein level by all three fusion proteins in U937 cells was plakoglobin. The plakoglobin promoter was cloned and shown to be induced by AML1-ETO in 32D cells. 93 Primary blast cells carrying one of the fusion proteins also significantly overexpressed plakoglobin in vivo.
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Plakoglobin is a co-activator of TCF and LEF transcription factors, 94 and mediates Wnt signaling. Plakoglobin binds to TCF/LEF transcription factors, localizes to the nucleus and activates the transcription of target genes like cyclin D1, c-myc and PPARd. Accordingly, enhanced transcriptional activity of plakoglobin by AML fusion proteins leads to induction of downstream signaling by transactivation of Wnt target genes in AML cells expressing AML1-ETO in vitro and in vivo. 93 Enhanced formation of plakoglobin-LEF-1 and b-catenin-LEF-1 complexes contributed to TCF-and LEF-dependent promoter transactivation. 93 Induction of c-myc by plakoglobin has previously been reported. 95 Our group could demonstrate plakoglobin binding to the c-myc promoter, c-myc promoter activity and increased c-myc expression in AML cells carrying one of the fusion proteins. Moreover, the AML fusion proteins induced expression of b-catenin, the key regulator within the Wnt pathway, and cyclin D1. 93 In addition to direct transcriptional activation, plakoglobin might compete with b-catenin for APC/axin binding and as a consequence lead to increased b-catenin-mediated transcription. Plakoglobin appears to be important in Wnt signaling induced by AML associated translocation products, since the colony-forming capacity of HSCs transduced with fusion proteins is abrogated upon plakoglobin inhibition through small interference RNA (siRNA) interference. 76 Retroviral transduction of plakoglobin into primitive murine hematopoietic progenitor cells preserved the immature phenotype during colony growth, suggesting enhanced self-renewal. 93 Furthermore, plakoglobin overexpression in myeloid 32D cells enhanced proliferation and clonal growth, and injection of plakoglobin-expressing 32D cells into syngeneic mice significantly accelerated the development of leukemia. 93 Moreover, overexpression of plakoglobin in HSCs blocks differentiation and selects a subset of early stem cells that is unable to differentiate in the presence of granulocyte colony-stimulating factor, respectively, granulocyte/macrophage colony-stimulating factor, thus suggesting a leukemogenic potential of a constitutively activated Wnt signaling. These data provide evidence that AML associated fusion proteins contribute to leukemogenesis at least partially by inducing plakoglobin expression and therefore targeting the Wnt signaling pathway. Wnt signaling is a common feature of several balanced translocations in AML in vitro and in vivo. Wnt signaling in hematopoietic progenitors leads to expansion and self-renewal of HSCs and progenitor cells. 20, 21, 54 AML fusion proteins have been observed to function partially by enhancing self-renewal as well. 96, 97 Therefore, it appears likely that the self-renewal capacity conferred by AML fusion proteins is at least partially mediated by Wnt signaling.
The Wnt inhibitory factor 1 (Wif-1) is an extracellular protein that negatively regulates the Wnt pathway by binding Wnt. 98 Thus, Wif-1 downregulation is supposed to contribute to Wnt pathway activation. In leukemias, promoter hypermethylation of genes involved in cell-cycle control and signaling is frequent. [99] [100] [101] [102] Chim et al. 103 provided evidence that Wif-1 was methylated in 47% of acute promyelocytic leukemia (APL) patients and in the APL cell line NB4 but not in normal bone marrow samples. Demethylation treatment of the APL cell line NB4 with 5-azacytidine (5-AC) led to progressive upregulation of Wif-1 in these cells confirming that promoter methylation suppresses Wif-1 gene expression in APL. 103 Hence, downregulation of Wif-1 might be another mechanism leading to activation of the Wnt pathway in APL that is typically associated with PML-RARa or PLZF-RARa. Interestingly, in APL patients, Wif-1 methylation was associated with young age and a higher leukocyte count. Remission rates were comparable in patients with or without Wif-1 methylation, but the projected 3-year disease-free survival was significantly inferior in patients with Wif-1 methylation as compared to those without, 103 hinting at a prognostic relevance of Wnt signaling in APL.
Cooperation of Flt3-ITD mutations with Wnt signaling in AML
Activating mutations of the type III RTK Flt3 occur in about 30% of patients with AML. 104 In-frame internal tandem duplications (ITD) at the juxtamembrane domain of the receptor are frequent. Flt3-ITD mutations result in ligand-independent kinase activation mediating proliferation and survival, block of myeloid differentiation, as well as induction of leukemic transformation in hematopoietic progenitor cell lines and primary mouse bone marrow. 76, [105] [106] [107] The mechanisms of leukemic transformation through Flt3-ITD mutations are not fully understood. Genes that are differentially expressed upon expression of Flt3-ITD were identified in the myeloid progenitor cell line 32Dcl3. 108 It appears that mutant Flt3 not only leads to enhanced signaling but also alters the quality of the signal. As a consequence, several signaling pathways become activated by mutant Flt3 that are not altered by ligand-induced wild-type signaling. Microarray analyses indicated that Frizzled-4, one of the Wnt receptors, can be induced by Flt3 in myeloid progenitor cells 32D/Flt3-ITD cells. 108, 109 Interestingly, hematopoietic cells either in cell culture or primary bone marrow blasts show significantly increased b-catenin protein levels. 109 The increases in b-catenin protein levels were associated with increased TCF/ LEF transcriptional activity as well as TCF-dependent induction of c-myc. These findings were recently complemented by data from Simon et al. 110 who used a luciferase reporter plasmid that was activated in response to binding by TCF/LEF. Increased activation of Wnt signaling in comparison to normal progenitor cells was observed in six out of seven AML cases harboring Flt3-ITD mutations. 110 Furthermore, GSK3b, a key player in canonical Wnt signaling, is inactivated by Akt(PKB; protein kinase B)-dependent phosphorylation. 111, 112 The phosphatidylinositol 3-kinase(PI3K)/Akt cascade is activated in most AML cases. [113] [114] [115] [116] In particular, it is activated by FLT3-ITD mutations, 117 suggesting that increased Wnt signaling in AML patients carrying such a mutation is at least partially due to GSK3b inactivation.
Taken together, these results suggest that Flt3-ITD might mediate its leukemogenic effects partially by activation of the Wnt signaling pathway.
Other mechanisms of aberrant Wnt signaling in AML
A considerable fraction of AML patients does show neither Flt3 mutations nor balanced translocations. Recent studies revealed aberrant Wnt signaling in AML cells that is independent from the occurrence of AML-associated fusion proteins or Flt3-ITD mutations.
Jamieson et al. 6 demonstrated that granulocyte macrophage progenitors have enhanced self-renewal capability as a result of aberrant activation of the Wnt/b-catenin pathway in granulocytic blast crisis CML resembling AML. Results from Simon et al. 110 also suggested that aberrant activation of the Wnt signaling pathway may contribute to the malignant phenotype in a high percentage of AML patients. A significant proportion of AML cases showed aberrant expression of components of the Wnt pathway, including Wnt-1, Wnt-2b and LEF-1 as potential mechanisms for an upregulation of b-catenin/TCF signaling. They also found that b-catenin expression is downregulated at days 5-7 of myelomonocytic differentiation of CD34-positive cells. 110 Retroviral transfection of a constitutively active bcatenin into normal primary human CD34 þ cells leads to persistence of a more immature cell population as confirmed by morphological examination and flow cytometry. Activated b-catenin protected normal CD34 þ progenitors from apoptosis. 110 In addition, increased transcriptional activity of the LEF/ TCF factors was detected in 64% of AML samples in comparison to normal progenitor cells. 110 LEF-1 is a transcriptional mediator of Wnt/b-catenin signaling, and was observed to be involved in leukemogenesis by demonstration of a TCF-and LEF-dependent promoter transactivation by AML-associated fusion proteins as described above. 93 Studies of Li et al. 118 revealed another potential role of LEF-1 in leukemogenesis of AML. This group was able to show a cooperation of LEF-1 with CBFa in vivo leading to activation of ELA2, a gene that is involved in leukemogenesis of a hereditary AML predisposition syndrome, severe congenital neutropenia (SCN). 118 Moreover, Skokowa et al. 119 demonstrated that LEF-1 is crucial for neutrophil granulocytopoiesis. Its reduced expression plays a critical role in the defective maturation program of myeloid progenitor cells in patients with SCN. 119 b-Catenin, the key regulator of the Wnt pathway, is expressed at various protein levels in AML patients. 120, 121 b-Catenin protein levels in AML cells differ from mRNA levels indicating translational and/or post-translational regulation by the Wnt pathway. b-Catenin expression was correlated with the clonogenic proliferation of AML-colony forming cells in methylcellulose, and more strikingly with self-renewal of leukemic cells, as assessed in vitro by a replating assay. 122 Furthermore, in survival analyses, b-catenin was suggested to be a new independent prognostic factor predicting poor event-free survival and shortened overall survival of AML patients. 121 Studies of breast and ovarian cancer, as well as pre-B-cellleukemia and multiple myeloma cells suggested that autocrine Wnt signals might contribute to the development of cancers. [122] [123] [124] A similar mechanism is also conceivable in AML.
Recently, Ma et al. 125 detected that SALL4 is an oncogene that is constitutively expressed in AML. In humans, the SALL gene family is involved in normal development, as well as in tumorigenesis. [126] [127] [128] [129] [130] [131] [132] During normal hematopoiesis SALL4 isoforms are expressed in the CD34 þ hematopoietic stem and progenitor cell population, and they are rapidly turned off (SALL4B), respectively, downregulated (SALL4A) in normal human bone marrow and peripheral blood.
125 SALL4 isoforms were constitutively expressed on the mRNA and the protein level in all primary human AML samples tested, as well as in all AML cell lines. SALL4B transgenic mice developed myelodysplastic syndrome (MDS)-like features and subsequently AML. 125 Two isoforms of SALL4, SALL4A and SALL4B could bind to bcatenin and synergistically enhanced the Wnt/b-catenin signaling pathway. In addition, SALL4 is directly activated by TCF/LEF within the canonical Wnt signaling pathway. 133 mRNA expression of two Wnt/b-catenin downstream target genes, c-myc and cyclin D1, is significantly upregulated in SALL4B transgenic mice. Therefore, constitutive expression of SALL4 causes MDS, respectively, AML most probably through the Wnt/b-catenin pathway. 125 In CML SALL4 expression was absent in the chronic phase, became detectable in the accelerated phase only in immature blasts, and was strongly positive in the blast phase, 125 a situation strongly resembling AML.
The idea of a crucial role of Wnt signaling in leukemogenesis was further supported by data from Ross et al. 134 who showed that Wnt signaling prevented adipocyte differentiation by inhibiting C/EBPa. C/EBPa is a major inducer of granulopoiesis and is frequently mutated in the FAB M2 subtype of AML. [135] [136] [137] [138] Taken together, these data provide evidence for the involvement of the Wnt/b-catenin pathway in the pathogenesis of AML. Paradoxically, although in most instances Wnt proteins induce proliferation and are associated with leukemogenesis, a small subset of Wnt5a hemizygous mice develop lymphoid and myeloid leukemia. 139 Moreover, Wnt5a-mediated activation of the non-canonical Wnt-Ca 2 þ pathway can inhibit the canonical pathway, suppresses cyclin D1 and negatively regulates proliferation. 140 Loss of this suppression may lead to hyperproliferation and leukemogenesis. Thus, Wnt5a appears to inhibit proliferation of hematopoietic cells and might function as a tumor suppressor in hematopoietic tissue. The hypothesis that Wnt signals not only contribute to proliferation and self-renewal in AML but partially also function as tumor suppressors is further supported by a study of de Toni et al. 141 This group was able to show that addition of different antagonists of the canonical Wnt/ b-catenin pathway, such as sFRP-1, Dkk-1 and Wnt5a to AML blasts or U937 cells induced resistance to daunorubicin, whereas incubation with the Wnt agonist Wnt3a increased chemosensitivity. Drug resistance mediated by sFRP-1 required GSK3b and nuclear factor-kB (NF-kB) suggesting a crosslink between Wnt signaling and NF-kB activation in AML. 141 Osteoblasts that play a key role in the maintenance of the hematopoietic niche were shown to support drug resistance of U937 cells adhering onto osteoblasts by triggering sFRP-1 secretion. 141 As a consequence Wnt proteins seem not only to support selfrenewal and proliferation of AML cells but can also partially act as tumor suppressors and chemosensitizers. This controversy might be closely related to the effects of Wnt signaling on specific target cells. We have recently shown that Wnt signaling enhances migratory properties in monocytes. 142 The importance of the target cell population is further emphasized by the finding that b-catenin induced self-renewal only occurred in a bcl-2 transgenic murine background. 73 This might even suggest that the outcome of Wnt signaling might be decided by additional stem cell regulatory factors. Moreover, it is likely that other signal transduction pathways, for example the Akt and Notch pathway, closely interact with Wnt signaling. 89 Fukumoto et al. 111 could show that expression of Wnt or DVL increases Akt activity. Activation of Akt-signaling is involved in Wnt3a-induced proliferation of fibroblasts.
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GSK3b that plays a major role within the Wnt pathway is a target of the phosphatidylinositol 3-kinase(PI3K)/Akt cascade, which is also activated in most AML cases. On the one hand, Aktdependent phosphorylation of GSK3b leading to its inactivation might be triggered by FLT3-ITD mutations as described above. Alternatively, GSK3b could be directly phosphorylated by integrin-linked kinase, which is also activated in AML by interactions with bone marrow stromal cells. 144 Thus, GSK3b might crosslink Wnt and PI3K/Akt pathways in AML. Indeed, Cheong et al. 145 could show that in some AML cases GSK3b is a target of Akt. However, this finding was not confirmed by other investigators. 146 Cooperation between Wnt and Notch in HSCs has recently been suggested by Duncan et al. 89 Furthermore, studies have demonstrated a role for Wnt and Notch in T-cell leukemias. 147 For example, Weng et al. 148 could show that over 50% of human T-ALL patients have activating mutations in Notch1. Deregulated T-cell proliferation might result from suppression of p53 and/or activation of the NF-kB by Notch. 149, 150 Both Notch and Wnt might also cooperate to contribute to leukemogenesis in AML.
Conclusions and future perspectives
AML is often characterized by activation of Wnt signaling and downstream effectors. An important step forward will be to analyze the therapeutic potential of this pathway in acute leukemias. Activated Wnt signaling is frequently found in various human cancers. Therefore, inhibition of this pathway might be a promising therapeutic target for cancer therapy. 151 Imatinib effectively inhibits constitutive activity of b-catenin signaling and suppresses proliferation of human colon cancer cells. 152 In a conditional Wnt-1 transgenic mouse tumor model, reduction of Wnt-1 signaling resulted in the regression of the Wnt-1 initiated primary mammary tumors and lung metastasis. 153 Moreover, blockade of Wnt signaling by either siRNA or use of specific antibodies inhibits tumor growth and induces apoptosis of cancer cells. 153, 154 Mazieres et al., 155 could show that inhibition of Wnt16 by the use of siRNA and an anti-Wnt16 antibody induces apoptosis in human ALL cells containing the t(1;19) translocation. Targeted Wnt blockage has to be handled with care to minimize risk for derogations of normal hematopoiesis. However, inhibition of Wnt signaling may provide a basis for the more selective targeting of cancer stem cells in leukemia.
